Pay in 4 interest-free payments of $6.94 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Additionally, two small studies in participants presenting with antiretroviral-induced neuropathy found significant reduction in subjects' mean pain intensity with oral ALCAR (1-3 g/day) for 4 to 24 weeks, but no effect on objective neurophysiological parameters was found (82, 83)
BPC-157s safety profile is notable in preclinical literature
Scoring Breakdown Independent lab verification of peptide purity (via HPLC), presence of contaminants, and transparent COAs
BPC-157 & TB-500 BPTB-2506 98.1% 10 mg Freeze-dried reference material Current product record Build your stack Study alongside other catalogue references
BPC-157's proposed mechanisms are based on pre-clinical animal research only
